Arvinas will present safety, pharmacokinetic, and pharmacodynamic data from its Phase 1 trial of ARV‑102 at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Denmark. The presentation, scheduled for March 18, 2026 from 3:30‑3:45 PM CET in Hall 180‑181, will cover modulation of neuroinflammation, α‑synuclein, LRRK2 activity, and dopaminergic repair in early human data.
ARV‑102 is an orally bioavailable PROTAC that selectively degrades leucine‑rich repeat kinase 2 (LRRK2), a protein implicated in Parkinson’s disease and progressive supranuclear palsy. The Phase 1 trial is enrolling Parkinson’s patients, and Arvinas plans to initiate a Phase 1b trial in PSP patients in the first half of 2026, pending regulatory feedback.
This presentation marks the first public disclosure of clinical data for ARV‑102, advancing Arvinas’s neurodegenerative pipeline and providing a potential disease‑modifying therapy for Parkinson’s disease, a high‑unmet‑need indication. The data will also validate Arvinas’s PROTAC platform in the central nervous system.
Arvinas recently reported a Q4 2025 earnings miss, with earnings per share of –$1.10 versus consensus of –$0.56 and revenue of $9.5 million against estimates of $35–37 million. The shortfall was driven by the absence of prior‑year collaboration payments and reduced revenue from the Novartis license, asset agreements, and the Pfizer collaboration. Despite the earnings miss, analysts have raised price targets, reflecting confidence in the pipeline.
Early Phase 1 data from healthy volunteers and Parkinson’s patients have shown that ARV‑102 is well tolerated, crosses the blood‑brain barrier, and reduces LRRK2 protein levels in both peripheral blood and cerebrospinal fluid. The upcoming presentation is a key milestone for Arvinas, as positive data could accelerate the company’s path to regulatory approval and broaden its market position in neurodegenerative disease therapeutics.
The presentation will also provide insights into the drug’s impact on neuroinflammation and α‑synuclein, offering a deeper understanding of its disease‑modifying potential and informing future clinical development plans.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.